deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT05122182

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)

An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Sponsor: The George Institute

Conditions COVID-19 SARS-CoV2 Infection
Interventions Candesartan Cilexetil Candesartan Placebo Repagermanium Repagermanium Placebo
Updated 9 times since 2021 Last updated: Sep 13, 2023 Started: Jan 7, 2022 Primary completion: Aug 15, 2022 Completion: Jan 28, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Withdrawal of funding support from the trial funder.

Other terminated trials from The George Institute

See all terminations from The George Institute

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

This PHASE2 trial investigates COVID-19 and SARS-CoV2 Infection and is currently terminated or withdrawn. The George Institute leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshotNot Yet Recruiting~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshotNot Yet Recruiting~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshotRecruiting~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshotTerminated~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotTerminated~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Apr 2023 — Oct 2023 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Apr 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Jan 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

  4. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The George Institute
  • University of Sydney
Data source: University of Sydney

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations